Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,533
archived clinical trials in
Chronic Obstructive Pulmonary Disease

Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/10/2015
1199.15.10027 Boehringer Ingelheim Investigational Site
mi
from
Tampa, FL
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/10/2015
1199.15.10027 Boehringer Ingelheim Investigational Site
mi
from
Tampa, FL
Click here to add this to my saved trials
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/10/2015
1275.1.01111 Boehringer Ingelheim Investigational Site
mi
from
Duluth, GA
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/10/2015
1275.1.01111 Boehringer Ingelheim Investigational Site
mi
from
Duluth, GA
Click here to add this to my saved trials
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/10/2015
Boehringer Ingelheim Investigational Site
mi
from
St. Louis, MO
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/10/2015
Boehringer Ingelheim Investigational Site
mi
from
St. Louis, MO
Click here to add this to my saved trials
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/10/2015
1218.61.01007 Boehringer Ingelheim Investigational Site
mi
from
Greensboro, NC
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/10/2015
1218.61.01007 Boehringer Ingelheim Investigational Site
mi
from
Greensboro, NC
Click here to add this to my saved trials
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/10/2015
Boehringer Ingelheim Investigational Site
mi
from
Columbus, OH
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/10/2015
Boehringer Ingelheim Investigational Site
mi
from
Columbus, OH
Click here to add this to my saved trials
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/10/2015
205.452.01309 Boehringer Ingelheim Investigational Site
mi
from
Dayton, OH
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/10/2015
205.452.01309 Boehringer Ingelheim Investigational Site
mi
from
Dayton, OH
Click here to add this to my saved trials
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/10/2015
205.452.01287 Boehringer Ingelheim Investigational Site
mi
from
Toledo, OH
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/10/2015
205.452.01287 Boehringer Ingelheim Investigational Site
mi
from
Toledo, OH
Click here to add this to my saved trials
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/10/2015
Boehringer Ingelheim Investigational Site
mi
from
Oklahoma City, OK
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/10/2015
Boehringer Ingelheim Investigational Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/10/2015
1245.28.10020 Boehringer Ingelheim Investigational Site
mi
from
Medford, OR
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/10/2015
1245.28.10020 Boehringer Ingelheim Investigational Site
mi
from
Medford, OR
Click here to add this to my saved trials
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/10/2015
1218.61.01031 Boehringer Ingelheim Investigational Site
mi
from
East Providence, RI
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/10/2015
1218.61.01031 Boehringer Ingelheim Investigational Site
mi
from
East Providence, RI
Click here to add this to my saved trials
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/10/2015
205.452.01013 Boehringer Ingelheim Investigational Site
mi
from
Gaffney, SC
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/10/2015
205.452.01013 Boehringer Ingelheim Investigational Site
mi
from
Gaffney, SC
Click here to add this to my saved trials
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/10/2015
Boehringer Ingelheim Investigational Site
mi
from
Greenville, SC
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/10/2015
Boehringer Ingelheim Investigational Site
mi
from
Greenville, SC
Click here to add this to my saved trials
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/10/2015
Boehringer Ingelheim Investigational Site
mi
from
Spartanburg, SC
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/10/2015
Boehringer Ingelheim Investigational Site
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/10/2015
205.419.01056 Boehringer Ingelheim Investigational Site
mi
from
Union, SC
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/10/2015
205.419.01056 Boehringer Ingelheim Investigational Site
mi
from
Union, SC
Click here to add this to my saved trials
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/10/2015
1222.51.01028 Boehringer Ingelheim Investigational Site
mi
from
Boerne, TX
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/10/2015
1222.51.01028 Boehringer Ingelheim Investigational Site
mi
from
Boerne, TX
Click here to add this to my saved trials
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/10/2015
Boehringer Ingelheim Investigational Site
mi
from
San Antonio, TX
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/10/2015
Boehringer Ingelheim Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/10/2015
1245.25.10182 Boehringer Ingelheim Investigational Site
mi
from
Morgantown, WV
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/10/2015
1245.25.10182 Boehringer Ingelheim Investigational Site
mi
from
Morgantown, WV
Click here to add this to my saved trials
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/10/2015
1237.26.61004 Boehringer Ingelheim Investigational Site
mi
from
Concord,
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/10/2015
1237.26.61004 Boehringer Ingelheim Investigational Site
mi
from
Concord,
Click here to add this to my saved trials
Innate Immune Response in COPD
Innate Immune Response in COPD
Status: Enrolling
Updated:  12/18/2015
VA Puget Sound Health Care System
mi
from
Seattle, WA
Innate Immune Response in COPD
Innate Immune Response in COPD
Status: Enrolling
Updated: 12/18/2015
VA Puget Sound Health Care System
mi
from
Seattle, WA
Click here to add this to my saved trials
Adverse Health Effects of Mainstream and Secondhand Hookah Smoke in NYC Hookah Bars
Adverse Health Effects of Mainstream and Secondhand Hookah Smoke in NYC Hookah Bars
Status: Enrolling
Updated:  12/18/2015
New York University School of Medicine
mi
from
New York, NY
Adverse Health Effects of Mainstream and Secondhand Hookah Smoke in NYC Hookah Bars
Adverse Health Effects of Mainstream and Secondhand Hookah Smoke in NYC Hookah Bars
Status: Enrolling
Updated: 12/18/2015
New York University School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Randomized Trial of Physical Activity Self-Management Intervention for Patients With COPD
Randomized Trial of Physical Activity Self-Management Intervention for Patients With COPD
Status: Enrolling
Updated:  12/24/2015
University of Texas Health Science Center at Tyler
mi
from
Tyler, TX
Randomized Trial of Physical Activity Self-Management Intervention for Patients With COPD
Randomized Trial of Physical Activity Self-Management Intervention for Patients With COPD
Status: Enrolling
Updated: 12/24/2015
University of Texas Health Science Center at Tyler
mi
from
Tyler, TX
Click here to add this to my saved trials
Apoptotic Cell (AC) Uptake by Human Alveolar Macrophages (AM)
Apoptotic Cell Ingestion by Normal Human Alveolar Macrophages
Status: Enrolling
Updated:  1/4/2016
VA Ann Arbor Healthcare System, Ann Arbor, MI
mi
from
Ann Arbor, MI
Apoptotic Cell (AC) Uptake by Human Alveolar Macrophages (AM)
Apoptotic Cell Ingestion by Normal Human Alveolar Macrophages
Status: Enrolling
Updated: 1/4/2016
VA Ann Arbor Healthcare System, Ann Arbor, MI
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Single Oral Dose of Dexamethasone Versus Five Days of Prednisone in Adult Asthma
A Randomized Double-Blind Controlled Trial of Single Oral Dose Dexamethasone Versus Five Days of Oral Prednisone in Acute Mild to Moderate Adult Asthma
Status: Enrolling
Updated:  1/5/2016
Alameda County Medical Center
mi
from
Oakland, CA
Single Oral Dose of Dexamethasone Versus Five Days of Prednisone in Adult Asthma
A Randomized Double-Blind Controlled Trial of Single Oral Dose Dexamethasone Versus Five Days of Oral Prednisone in Acute Mild to Moderate Adult Asthma
Status: Enrolling
Updated: 1/5/2016
Alameda County Medical Center
mi
from
Oakland, CA
Click here to add this to my saved trials
Safety Study of Nebivolol for COPD Patients
Nebivolol in Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  1/11/2016
University of Chicago Medical Center
mi
from
Chicago, IL
Safety Study of Nebivolol for COPD Patients
Nebivolol in Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 1/11/2016
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  1/11/2016
205.440.1015 Boehringer Ingelheim Investigational Site
mi
from
Jasper, AL
Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 1/11/2016
205.440.1015 Boehringer Ingelheim Investigational Site
mi
from
Jasper, AL
Click here to add this to my saved trials
Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  1/11/2016
205.452.01011 Boehringer Ingelheim Investigational Site
mi
from
Clearwater, FL
Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 1/11/2016
205.452.01011 Boehringer Ingelheim Investigational Site
mi
from
Clearwater, FL
Click here to add this to my saved trials
Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  1/11/2016
1268.17.01045 Boehringer Ingelheim Investigational Site
mi
from
Deland, FL
Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 1/11/2016
1268.17.01045 Boehringer Ingelheim Investigational Site
mi
from
Deland, FL
Click here to add this to my saved trials
Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  1/11/2016
205.452.01060 Boehringer Ingelheim Investigational Site
mi
from
Winter Park, FL
Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 1/11/2016
205.452.01060 Boehringer Ingelheim Investigational Site
mi
from
Winter Park, FL
Click here to add this to my saved trials
Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  1/11/2016
205.452.01047 Boehringer Ingelheim Investigational Site
mi
from
Austell, GA
Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 1/11/2016
205.452.01047 Boehringer Ingelheim Investigational Site
mi
from
Austell, GA
Click here to add this to my saved trials
Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  1/11/2016
Boehringer Ingelheim Investigational Site
mi
from
Albuquerque, NM
Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 1/11/2016
Boehringer Ingelheim Investigational Site
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  1/11/2016
Boehringer Ingelheim Investigational Site
mi
from
Charlotte, NC
Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 1/11/2016
Boehringer Ingelheim Investigational Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  1/11/2016
1222.29.11003 Boehringer Ingelheim Investigational Site
mi
from
Raleigh, NC
Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 1/11/2016
1222.29.11003 Boehringer Ingelheim Investigational Site
mi
from
Raleigh, NC
Click here to add this to my saved trials
Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  1/11/2016
Boehringer Ingelheim Investigational Site
mi
from
Columbus, OH
Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 1/11/2016
Boehringer Ingelheim Investigational Site
mi
from
Columbus, OH
Click here to add this to my saved trials
Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  1/11/2016
1222.25.25014 Boehringer Ingelheim Investigational Site
mi
from
Seneca, SC
Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 1/11/2016
1222.25.25014 Boehringer Ingelheim Investigational Site
mi
from
Seneca, SC
Click here to add this to my saved trials
Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  1/11/2016
1160.129.32082 Boehringer Ingelheim Investigational Site
mi
from
Knoxville, TN
Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 1/11/2016
1160.129.32082 Boehringer Ingelheim Investigational Site
mi
from
Knoxville, TN
Click here to add this to my saved trials
Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  1/11/2016
Boehringer Ingelheim Investigational Site
mi
from
Houston, TX
Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 1/11/2016
Boehringer Ingelheim Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  1/11/2016
Boehringer Ingelheim Investigational Site
mi
from
Richmond, VA
Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 1/11/2016
Boehringer Ingelheim Investigational Site
mi
from
Richmond, VA
Click here to add this to my saved trials
Ventilator Adapters for Combivent Respimat
Open Label, Non-randomised, 1-day Trial to Characterize the Performance of Two Adapter Devices Designed to Permit Use of the Respimat® Inhaler Device With Patients Requiring Mechanical Ventilation.
Status: Enrolling
Updated:  1/19/2016
205.452.01199 Boehringer Ingelheim Investigational Site
mi
from
Danbury, CT
Ventilator Adapters for Combivent Respimat
Open Label, Non-randomised, 1-day Trial to Characterize the Performance of Two Adapter Devices Designed to Permit Use of the Respimat® Inhaler Device With Patients Requiring Mechanical Ventilation.
Status: Enrolling
Updated: 1/19/2016
205.452.01199 Boehringer Ingelheim Investigational Site
mi
from
Danbury, CT
Click here to add this to my saved trials
Ventilator Adapters for Combivent Respimat
Open Label, Non-randomised, 1-day Trial to Characterize the Performance of Two Adapter Devices Designed to Permit Use of the Respimat® Inhaler Device With Patients Requiring Mechanical Ventilation.
Status: Enrolling
Updated:  1/19/2016
1199.15.10110 Boehringer Ingelheim Investigational Site
mi
from
Fort Worth, TX
Ventilator Adapters for Combivent Respimat
Open Label, Non-randomised, 1-day Trial to Characterize the Performance of Two Adapter Devices Designed to Permit Use of the Respimat® Inhaler Device With Patients Requiring Mechanical Ventilation.
Status: Enrolling
Updated: 1/19/2016
1199.15.10110 Boehringer Ingelheim Investigational Site
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Beneficial Effects of Quercetin in Chronic Obstructive Pulmonary Disease (COPD)
Phase I/II Study to Determine the Safety and Efficacy of Quercetin in COPD Patients
Status: Enrolling
Updated:  1/20/2016
University of Michigan
mi
from
Ann Arbor, MI
Beneficial Effects of Quercetin in Chronic Obstructive Pulmonary Disease (COPD)
Phase I/II Study to Determine the Safety and Efficacy of Quercetin in COPD Patients
Status: Enrolling
Updated: 1/20/2016
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Adjusting to Chronic Conditions Using Education, Support, and Skills
Cognitive Behavioral Therapy in Primary Care: Treating the Medically Ill
Status: Enrolling
Updated:  1/25/2016
VA Medical Center, Oklahoma City
mi
from
Oklahoma City, OK
Adjusting to Chronic Conditions Using Education, Support, and Skills
Cognitive Behavioral Therapy in Primary Care: Treating the Medically Ill
Status: Enrolling
Updated: 1/25/2016
VA Medical Center, Oklahoma City
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Adjusting to Chronic Conditions Using Education, Support, and Skills
Cognitive Behavioral Therapy in Primary Care: Treating the Medically Ill
Status: Enrolling
Updated:  1/25/2016
Michael E. DeBakey VA Medical Center, Houston, TX
mi
from
Houston, TX
Adjusting to Chronic Conditions Using Education, Support, and Skills
Cognitive Behavioral Therapy in Primary Care: Treating the Medically Ill
Status: Enrolling
Updated: 1/25/2016
Michael E. DeBakey VA Medical Center, Houston, TX
mi
from
Houston, TX
Click here to add this to my saved trials
N-Acetylcysteine for Patients With COPD and Chronic Bronchitis
Effects of High-Dose N-Acetylcysteine on Respiratory Health Status in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis: A Randomized, Placebo-Controlled Trial-3
Status: Enrolling
Updated:  1/25/2016
Univ of Minnesota
mi
from
Minneapolis, MN
N-Acetylcysteine for Patients With COPD and Chronic Bronchitis
Effects of High-Dose N-Acetylcysteine on Respiratory Health Status in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis: A Randomized, Placebo-Controlled Trial-3
Status: Enrolling
Updated: 1/25/2016
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Innate and Adaptive Immunity in Individuals Experiencing Chronic Obstructive Pulmonary Disease Exacerbations
Innate and Adaptive Immunity in COPD Exacerbations: Prospective Cohort Study
Status: Enrolling
Updated:  1/28/2016
University of Michigan at Ann Arbor
mi
from
Ann Arbor, MI
Innate and Adaptive Immunity in Individuals Experiencing Chronic Obstructive Pulmonary Disease Exacerbations
Innate and Adaptive Immunity in COPD Exacerbations: Prospective Cohort Study
Status: Enrolling
Updated: 1/28/2016
University of Michigan at Ann Arbor
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
T Lymphocyte Cells in Individuals Experiencing an Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Innate and Adaptive Immunity in COPD Exacerbations: Surgical Volunteers
Status: Enrolling
Updated:  1/28/2016
University of Michigan at Ann Arbor
mi
from
Ann Arbor, MI
T Lymphocyte Cells in Individuals Experiencing an Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Innate and Adaptive Immunity in COPD Exacerbations: Surgical Volunteers
Status: Enrolling
Updated: 1/28/2016
University of Michigan at Ann Arbor
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
T Lymphocyte Cells in Individuals Experiencing an Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Innate and Adaptive Immunity in COPD Exacerbations: Surgical Volunteers
Status: Enrolling
Updated:  1/28/2016
VA Ann Arbor Healthcare System
mi
from
Ann Arbor, MI
T Lymphocyte Cells in Individuals Experiencing an Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Innate and Adaptive Immunity in COPD Exacerbations: Surgical Volunteers
Status: Enrolling
Updated: 1/28/2016
VA Ann Arbor Healthcare System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Changes in Cytokine Levels During an Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Innate and Adaptive Immunity in COPD Exacerbations: Severe AE-COPD Clinical Course Study
Status: Enrolling
Updated:  1/28/2016
University of Michigan at Ann Arbor
mi
from
Ann Arbor, MI
Changes in Cytokine Levels During an Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Innate and Adaptive Immunity in COPD Exacerbations: Severe AE-COPD Clinical Course Study
Status: Enrolling
Updated: 1/28/2016
University of Michigan at Ann Arbor
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Mission Hills, CA
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Mission Hills, CA
Click here to add this to my saved trials
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
San Diego, CA
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
San Diego, CA
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials